Alnylam Raises FY25 Revenue Guidance to $2.65B-$2.8B, Exceeds Consensus Estimate of $3.02B.

Alnylam Pharmaceuticals raised its FY25 revenue outlook to $2.65B-$2.8B, exceeding consensus estimates of $3.02B. The company is advancing several key programs in its pipeline, including the TRITON-CM Phase 3 trial of nucresiran in ATTR-CM and the TRITON-PN Phase 3 trial for nucresiran in hATTR-PN. Alnylam aims to deliver on its P5x25 goals and achieve sustainable profitability.

Alnylam Pharmaceuticals (ALNY) has significantly raised its fiscal 2025 revenue outlook, exceeding consensus estimates. The company now expects total net product revenues to range between $2.65 billion and $2.8 billion, surpassing the previous consensus of $3.02 billion. This upward revision reflects strong performance in the second quarter of 2025 and robust expectations for future growth.

In its Q2 2025 earnings report, Alnylam reported total revenue of $773.69 million, a 17% year-over-year increase, and beat analyst estimates of $638.55 million [1]. Despite a widening net loss of $-66.28 million, the company's strategic focus on innovation and commercial product launches has led to a positive outlook.

Key highlights include the successful launch of AMVUTTRA, which contributed $491.95 million in net product revenues, representing a 77% year-over-year growth. The company also achieved significant milestones in its pipeline, with approximately 1,400 ATTR-CM patients on AMVUTTRA (vutrisiran) as of June 30, 2025 [2].

Alnylam's TRITON-CM Phase 3 trial of nucresiran in ATTR-CM and TRITON-PN Phase 3 trial for nucresiran in hATTR-PN are advancing, positioning the company to deliver on its P5x25 goals and achieve sustainable profitability.

The company's stock price surged by 12.07% on July 31, 2025, following the earnings announcement, reaching a 52-week high. Analysts remain optimistic, with Needham maintaining a Buy rating and raising the price forecast from $377 to $478 [2].

References:
[1] https://www.ainvest.com/news/alnylam-pharmaceuticals-2025-q2-earnings-misses-targets-net-loss-widens-292-2508/
[2] https://www.inkl.com/news/alnylam-pharmaceuticals-q2-earnings-crush-estimates-stock-hits-52-week-high-on-upbeat-forecast